Humacyte, Inc. (HUMA) Social Stream



Humacyte, Inc. (HUMA): $2.78

0.18 (+6.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HUMA to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

HUMACYTE INC (HUMA) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering HUMA.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-15 5 $20 $16 $17.8 $2.58 589.92%
2022-01-31 6 $20 $16 $17.8 $2.58 589.92%
2022-02-01 6 $20 $12 $16.8 $2.58 551.16%
2022-03-31 6 $20 $10 $15.833 $2.58 513.68%
2022-05-16 5 $19 $4 $13.8 $2.58 434.88%
2022-05-17 5 $19 $4 $13 $2.58 403.88%
2022-08-15 5 $18 $4 $11.2 $2.58 334.11%
2022-11-15 4 $18 $2.75 $8.75 $2.58 239.15%
2022-12-19 4 $18 $2.75 $8.15 $2.58 215.89%

The Trend in the Analyst Price Target


Over the past 126 days, HUMA's average price target has gone down $3.05.

HUMA reports an average of 167.78% for its upside potential over the past 46 weeks.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2022-03-31 5 19 10.00 15.000 7.06 112.46%
2022-03-31 6 20 10.00 15.833 7.06 124.26%
2022-05-17 5 19 4.00 13.000 4.73 174.84%
2022-08-15 4 18 4.00 11.200 4.78 134.31%
2022-11-15 5 18 2.75 8.750 2.97 194.61%

HUMA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2 3 0 0 1 1 4

The Trend in the Broker Recommendations


Over the past 15 months, HUMA's average broker recommendation rating improved by 0.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for HUMA as an investment opportunity.

  • HUMA has a greater upside potential (average analyst target price relative to current price) than 1275.4% of all US stocks.
  • In the context of all US stocks, HUMACYTE INC's average analyst price target is higher than 210.16% of them.
  • In terms of how HUMACYTE INC fares relative to all US stocks, note that its variance in analysts' estimates is lower than -951.54% of that group.
  • HUMACYTE INC's number of analysts covering the stock is greater than 451.35% of Healthcare stocks.

In terms of price targets and recommendations offered by analysts, the stocks in the Pharmaceutical Products industry with the ratings most similar to HUMACYTE INC are TSHA, CDAK, and OPT.

Make investment decisions regarding HUMA using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5465 seconds.